feedburner

Enter your email address:

Delivered by FeedBurner

Safety, efficacy main concerns with Russia's COVID-19 vaccine: Nobel laureate Peter Doherty

Sputnik V has been developed by the Gamaleya Research Institute of
Epidemiology and Microbiology along with the Russian Direct Investment
Fund (RDIF). The vaccine has not been tested in Phase 3 or larger
clinical trials.

https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/safety-efficacy-main-concerns-with-russias-covid-19-vaccine-nobel-laureate-peter-doherty/articleshow/77588180.cms



0 comments:

Post a Comment